Ardelyx (ARDX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
19 May, 2026Executive summary
Proposal to amend the 2014 Equity Incentive Award Plan by adding 9,000,000 shares to the reserve, supporting growth and talent retention through 2027.
The amendment is positioned as essential for scaling operations, commercializing products, and building the pipeline.
Forward-looking statements highlight plans for continued growth, commercialization, and pipeline development, with risks noted regarding talent competition and capital resources.
Voting matters and shareholder proposals
Stockholders are asked to approve the amendment to the equity plan at the June 16, 2026 annual meeting.
The Board of Directors, after review with independent advisors, strongly recommends voting in favor of the proposal.
Board of directors and corporate governance
The Compensation and Leadership Development Committee conducted a thorough evaluation and recommended the equity plan amendment to the Board.
Directors, officers, and employees may be participants in the proxy solicitation, with their interests disclosed in the proxy statement.
Latest events from Ardelyx
- IBSRELA and XPHOZAH are set for robust growth, targeting $1B and $750M revenues by 2029.ARDX
Jefferies Global Healthcare Conference 20263 Jun 2026 - Board seeks approval to expand equity plan, supporting growth and talent retention through 2027.ARDX
Proxy filing26 May 2026 - IBSRELA targets $1B+ sales by 2029, with pipeline and cash flow fueling future growth.ARDX
Leerink Global Healthcare Conference 20265 May 2026 - Q1 2026 revenue up 38% to $93.4M, IBSRELA up 58%, net loss narrows, guidance reaffirmed.ARDX
Q1 20264 May 2026 - Proxy covers director elections, say-on-pay, auditor ratification, and equity plan amendment.ARDX
Proxy filing29 Apr 2026 - IBSRELA revenue jumped 73% in 2025, fueling 22% total growth and a strong 2026 outlook.ARDX
Q4 202510 Apr 2026 - Revenue and commercial momentum accelerate as innovative therapies expand and pipeline development advances.ARDX
43rd Annual J.P. Morgan Healthcare Conference 202513 Feb 2026 - TDAPA application for XPHOZAH was declined to protect patient access amid CMS policy changes.ARDX
Business Update3 Feb 2026 - Q2 revenue soared 228% to $73.2M, but XPHOZAH faces 2025 Medicare reimbursement risk.ARDX
Q2 20242 Feb 2026